Inventor · disambiguated record
Sung Wuk Kim
Also filed as: KIM SUNG WUK
30 granted patents·23 pending applications·103 citations·filing 2007–2024
95Inventor score
Files withKIM SUNG WUK20HANALL BIOPHARMA CO LTD17IMMUNOMET THERAPEUTICS INC10HANALL PHARMACEUTICAL CO LTD4CHEON HYAE GYEONG1
Top patents by PatentIndex Score
53 records- 0190US9133110B2Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredientKIM SUNG WUK·Filed 2011·Granted Sep 15, 2015·14 cites·4 claims
- 0287US8058312B2N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the sameKIM SUNG WUK·Filed 2008·Granted Nov 15, 2011·10 cites·17 claims
- 0387US2025026835A1Antibody binding to fcrn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 0486US9539238B2Pharmaceutical composition comprising a biguanide derivative as an active ingredient for preventing or treating glioblastomaIMMUNOMET THERAPEUTICS INC·Filed 2016·Granted Jan 10, 2017·5 cites·7 claims
- 0585US9540325B2N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the sameKIM SUNG WUK·Filed 2012·Granted Jan 10, 2017·10 cites·22 claims
- 0685US9464042B2Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredientIMMUNOMET THERAPEUTICS INC·Filed 2015·Granted Oct 11, 2016·4 cites·3 claims
- 0784US10544226B2Antibody binding to FcRn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2015·Granted Jan 28, 2020·4 cites·21 claims
- 0884US9416098B2Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredientKIM SUNG WUK·Filed 2011·Granted Aug 16, 2016·6 cites·8 claims
- 0984US9321742B2N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the sameKIM SUNG WUK·Filed 2012·Granted Apr 26, 2016·8 cites·15 claims
- 1084US8648111B2N1-2-thiophene-2-ylethyl-N2-substituted biguanide derivate, preparation method thereof, and pharmaceutical composition containing the same as active ingredientsKIM SUNG WUK·Filed 2009·Granted Feb 11, 2014·9 cites·12 claims
- 1184US8076377B2N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the sameKIM SUNG WUK·Filed 2008·Granted Dec 13, 2011·10 cites·4 claims
- 1284US2024092913A1Antibody binding to fcrn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 1383US11613578B2Antibody binding to FCRN for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2019·Granted Mar 28, 2023·1 cites·23 claims
- 1483US10626085B2Biguanide compound and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2015·Granted Apr 21, 2020·3 cites·7 claims
- 1581US8642647B2N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative, preparation method thereof, and pharmaceutical composition containing sameKIM SUNG WUK·Filed 2009·Granted Feb 4, 2014·6 cites·15 claims
- 1681US2023235063A1Antibody binding to fcrn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 1778US10058558B2Pharmaceutical composition comprising N1-cyclic amine-N5-substituted biguanide derivatives as an ingredient for preventing or treating fibrosisIMMUNOMET THERAPEUTICS INC·Filed 2014·Granted Aug 28, 2018·3 cites·10 claims
- 1875US10336825B2Antibody binding to FcRn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2017·Granted Jul 2, 2019·1 cites·4 claims
- 1975US8394845B2Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitorKIM SUNG WUK·Filed 2011·Granted Mar 12, 2013·4 cites·10 claims
- 2074US10590081B2Guanidine compounds and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2015·Granted Mar 17, 2020·2 cites·5 claims
- 2173US9993446B2Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredientIMMUNOMET THERAPEUTICS INC·Filed 2016·Granted Jun 12, 2018·1 cites·7 claims
- 2269US8541474B2N,N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the sameKIM SUNG WUK·Filed 2011·Granted Sep 24, 2013·1 cites·3 claims
- 2366US9068019B2Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing sameKIM SUNG WUK·Filed 2010·Granted Jun 30, 2015·1 cites·8 claims
- 2463US10376480B2Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredientIMMUNOMET THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·0 cites·6 claims
- 2563US2019135917A1Antibody binding to fcrn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2019·Application pending·0 cites
- 2661US2011123612A1Pharmaceutical preparation containing non-dihydropyridine calcium channel blocker and angiotensin-2 receptor blockerKIM SUNG WUK·Filed 2009·Application pending·0 cites
- 2760US2011052683A1Pharmaceutical preparation for treating cardiovascular diseaseHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 2860US2011111021A1Pharmaceutical preparationHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 2960US2011038931A1Composite preparationHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 3059US11572341B2Biguanide compound and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2020·Granted Feb 7, 2023·0 cites·5 claims
- 3157US2008241240A1Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitorsHANALL PHARMACEUTICAL CO LTD·Filed 2008·Application pending·0 cites
- 3255US2010047341A1Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theoryHANALL PHARMACEUTICAL CO LTD·Filed 2007·Application pending·0 cites
- 3349US2014235558A1Pharmaceutical composition having activity of anticancerHANALL BIOPHARMA CO LTD·Filed 2013·Application pending·0 cites
- 3449US2011111022A1Pharmaceutical formulationHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 3548US2012015032A1Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the sameKIM SUNG WUK·Filed 2008·Application pending·0 cites
- 3648US2011117194A1Pharmaceutical formulation containing angiotensin-ii receptor blockerHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 3747US2010272797A1Pharmaceutical Composition for Treating Hepatitis C Virus Infection Comprising HMG-COA Reductase Inhibitor and Bile AcidHANALL PHARMACEUTICAL CO LTD·Filed 2008·Application pending·0 cites
- 3846US8642083B2Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitorsKIM SUNG WUK·Filed 2007·Granted Feb 4, 2014·0 cites·42 claims
- 3944US12377061B2Composition for promoting hair growth comprising a guanine derivativeKOREA RES INST BIOSCIENCE & BIOTECHNOLOGY·Filed 2019·Granted Aug 5, 2025·0 cites·9 claims
- 4044US10280207B2FcRn-specific human antibody and composition for treatment of autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2014·Granted May 7, 2019·0 cites·5 claims
- 4144US2014235559A1Anti-cancer pharmaceutical compositionKIM SUNG-WUK·Filed 2011·Application pending·0 cites
- 4243US2010143470A1Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockersHANALL PHARMACEUTICAL CO LTD·Filed 2007·Application pending·0 cites
- 4342US9580490B2Uses of modified human tumor necrosis factor receptor-1 polypeptideHANALL BIOPHARMA CO LTD·Filed 2013·Granted Feb 28, 2017·0 cites·13 claims
- 4442US8722674B21,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the sameCHEON HYAE GYEONG·Filed 2008·Granted May 13, 2014·0 cites·5 claims
- 4541US11465989B2Guanidine compounds and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2015·Granted Oct 11, 2022·0 cites·6 claims
- 4641US8895500B2Modified human tumor necrosis factor receptor-I polypeptide or fragment thereof, and method for preparing sameKIM SUNG WUK·Filed 2011·Granted Nov 25, 2014·0 cites·18 claims
- 4741US2011294733A1Modified human thrombopoietin polypeptide fragment and manufacturing method thereofKIM SUNG WUK·Filed 2010·Application pending·0 cites
- 4840US2014377346A1Bosentan controlled release oral preparationHANALL BIOPHARMA CO LTD·Filed 2013·Application pending·0 cites
- 4939US8754037B2Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing sameKIM SUNG WUK·Filed 2011·Granted Jun 17, 2014·0 cites·24 claims
- 5037US2017305861A1Heteroaryl compounds comprising nitrogen and use thereofIMMUNOMET THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Sung Wuk Kim files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →